Society for Immunotherapy of Cancer (SITC) 2022

Boston, MA

A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models.

SPEAKER : Ravikumar Muthuswamy

World Vaccine Congress Washington 2022

Washington | DC

Novel Vaccinia Enhanced Template (VET) Oncolytic Platform

SPEAKER : Steve Thorne

TGF β for Immuno-Oncology Drug Development

Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus

SPEAKER : Steve Thorne

13TH INTERNATIONAL ONCOLYTIC VIRUS CONFERENCEOncolytic Viruses Symposium

The VET Platform: Re-targeting Oncolytic Vaccinia Virus to Tumors through Expression of Chemokine Receptors

SPEAKER : Steve Thorne

Oncolytic Virotherapy Summit

Boston | MA

The Design of Oncolytic Viral Therapies for Intravenous Delivery

SPEAKER : Steve Thorne

Oncolytic Viruses Symposium

Oxford Global

A Dual Pipeline Strategy Bringing Potent Vaccinia-Based Oncolytic Immunotherapies to the Clinic

SPEAKER : Steve Thorne